Refractory Primary Mediastinal Large B-Cell Cell Lymphoma

DBCOND0135857Hematologic Neoplasms

Refractory Primary Mediastinal Large B-Cell Cell Lymphoma is the indication for 3 drugs in DrugBank. It is covered by 4 curated, structured indications.

Also known as: Primary mediastinal large B-cell lymphoma refractory · refractory Primary Mediastinal Large B-Cell Lymphoma · refractory, primary Mediastinal Large B-cell Lymphoma · Primary Mediastinal Large B-Cell Lymphoma-Refractory
Classified under: Hematologic Neoplasms
Indicated drugs: Epcoritamab
Lisocabtagene maraleucel
Pembrolizumab

Resolves to

Vocabularies

MedDRA10023701UMLSC0855154

What you can answer from here — as of October 22, 2026

3Indicated drugsWith each drug's targets and mechanism

Listed above

4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

31Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Refractory Primary Mediastinal Large B-Cell Cell Lymphoma share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account